Iovance BiotherapeuticsIOVA
IOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 838
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $7.88M | Put options by funds: $6.57M
9% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 91
8% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 53
0% more funds holding
Funds holding: 299 [Q4 2024] → 299 (+0) [Q1 2025]
6.22% less ownership
Funds ownership: 79.24% [Q4 2024] → 73.02% (-6.22%) [Q1 2025]
55% less capital invested
Capital invested by funds: $1.79B [Q4 2024] → $798M (-$989M) [Q1 2025]
71% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 2 (-5) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
11%
downside
Avg. target
$11.50
413%
upside
High target
$25
1,016%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
UBS David Dai | 11%downside $2 | Neutral Downgraded | 16 May 2025 |
Goldman Sachs Andrea Tan | 257%upside $8 | Buy Maintained | 12 May 2025 |
Mizuho Mara Goldstein | 346%upside $10 | Outperform Maintained | 12 May 2025 |
Barclays Peter Lawson | 79%upside $4 | Overweight Maintained | 12 May 2025 |
Chardan Capital Geulah Livshits | 1,016%upside $25 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 387 articles about IOVA published over the past 30 days
Neutral
Accesswire
16 minutes ago
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153180&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
16 minutes ago
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / WHY: New York, N.Y., June 15, 2025.
Neutral
PRNewsWire
56 minutes ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
Accesswire
1 hour ago
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153164&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
4 hours ago
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153133&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
5 hours ago
IOVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").
Neutral
Accesswire
5 hours ago
July 14, 2025 Deadline Approaching: Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153121&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
17 hours ago
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
NEW YORK, NY / ACCESS Newswire / June 14, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153088&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Neutral
GlobeNewsWire
1 day ago
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Charts implemented using Lightweight Charts™